Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06864988 | 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | PHASE3 | ACTIVE NOT_RECRUITING | 480 | — | — | Mar 3, 2025 | Jun 1, 2028 | Jun 1, 2026 | 95 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| 4D-150 IVT (3E10 vg/eye) | EXPERIMENTAL | - |
| Aflibercept (AFLB) 2 mg IVT | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| 4D-150 IVT (3E10 vg/eye) | BIOLOGICAL | If randomized to the 4D-150 treatment arm, 4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1 |
| EYLEA® (aflibercept) Injection 2 mg (0.05mL) | BIOLOGICAL | Eylea (aflibercept) will be administered at applicable visits |
Inclusion Criteria: * ≥50 years of age at time of consent * Treatment naïve MNV secondary to nAMD in the study eye * Active subfoveal MNV or juxtafoveal/ extrafoveal MNV with a subfoveal component (where activity is defined as evidence of SRF, IRF, subretinal hyperreflective material, or leakage) i...